MHMalte Hellwig

Malte Hellwig

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Malte Hellwig has a total of 42 co-authors. Here are the top co-authors by number of shared publications:

  • Ulrich Schüller

    Research Institute Children’s Cancer Center Hamburg, Hamburg, Germany

    5 shared publications
  • Judith Niesen

    Department of Pediatric Hematology and Oncology, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany; Research Institute Children's Cancer Centre Hamburg, Hamburg, Germany

    4 shared publications
  • Daniel J. Merk

    Center for Neuropathology, Ludwig-Maximilians-University, Munich, Germany

    3 shared publications
  • Melanie Schoof

    Department of Pediatric Hematology and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

    3 shared publications
  • Michael Spohn

    Research Institute Children's Cancer Centre Hamburg, Hamburg, Germany

    3 shared publications
  • Beat Lutz

    Institute of Physiological Chemistry, University Medical Center of the Johannes Gutenberg University, Mainz, Germany

    2 shared publications

Latest Publications

  • Pik3ca mutations significantly enhance the growth of SHH medulloblastoma and lead to metastatic tumour growth in a novel mouse model

    by Judith Niesen, Jasmin Ohli, Jan Sedlacik, Lasse Dührsen, Malte Hellwig, Michael Spohn, Till Holsten, Ulrich Schüller


  • Open Access

    The basic helix‐loop‐helix transcription factor TCF4 impacts brain architecture as well as neuronal morphology and differentiation

    by Melanie Schoof, Malte Hellwig, Luke Harrison, Dörthe Holdhof, Marlen C. Lauffer, Judith Niesen, Sanamjeet Virdi, Daniela Indenbirken, Ulrich Schüller

    Germline mutations in the basic helix‐loop‐helix transcription factor 4 (TCF4) cause the Pitt–Hopkins syndrome (PTHS), a developmental disorder with severe intellectual disability. Here, we report findings from a new mouse model with a central nervous system‐specific truncation of Tcf4 leading to severe phenotypic abnormalities. Furthermore, it allows the study of a complete TCF4 knockout in adult mice, circumventing early postnatal lethality of previously published mouse models. Our data suggest that a TCF4 truncation results in an impaired hippocampal architecture affecting both the dentate gyrus as well as the cornu ammonis. In the cerebral cortex, loss of TCF4 generates a severe differentiation delay of neural precursors. Furthermore, neuronal morphology was critically affected with shortened apical dendrites and significantly increased branching of dendrites. Our data provide novel information about the role of Tcf4 in brain development and may help to understand the mechanisms leading to intellectual deficits observed in patients suffering from PTHS.


  • Open Access

    The transcriptional coactivator and histone acetyltransferase CBP regulates neural precursor cell development and migration

    by Melanie Schoof, Michael Launspach, Dörthe Holdhof, Lynhda Nguyen, Verena Engel, Severin Filser, Finn Peters, Jana Immenschuh, Malte Hellwig, Judith Niesen, et al.

    CREB (cyclic AMP response element binding protein) binding protein (CBP, CREBBP) is a ubiquitously expressed transcription coactivator with intrinsic histone acetyltransferase (KAT) activity. Germline mutations within theCBPgene are known to cause Rubinstein-Taybi syndrome (RSTS), a developmental disorder characterized by intellectual disability, specific facial features and physical anomalies. Here, we investigate mechanisms of CBP function during brain development in order to elucidate morphological and functional mechanisms underlying the development of RSTS. Due to the embryonic lethality of conventional CBP knockout mice, we employed a tissue specific knockout mouse model (hGFAP-cre::CBPFl/Fl, mutant mouse) to achieve a homozygous deletion of CBP in neural precursor cells of the central nervous system.Our findings suggest that CBP plays a central role in brain size regulation, correct neural cell differentiation and neural precursor cell migration. We provide evidence that CBP is both important for stem cell viability within the ventricular germinal zone during embryonic development and for unhindered establishment of adult neurogenesis. Prominent histological findings in adult animals include a significantly smaller hippocampus with fewer neural stem cells. In the subventricular zone, we observe large cell aggregations at the beginning of the rostral migratory stream due to a migration deficit caused by impaired attraction from the CBP-deficient olfactory bulb. The cerebral cortex of mutant mice is characterized by a shorter dendrite length, a diminished spine number, and a relatively decreased number of mature spines as well as a reduced number of synapses.In conclusion, we provide evidence that CBP is important for neurogenesis, shaping neuronal morphology, neural connectivity and that it is involved in neuronal cell migration. These findings may help to understand the molecular basis of intellectual disability in RSTS patients and may be employed to establish treatment options to improve patients’ quality of life.


  • Preferential sensitivity to HDAC inhibitors in tumors with CREBBP mutation

    by Malte Hellwig, Daniel J. Merk, Beat Lutz, Ulrich Schüller

    Mutations in the gene encoding for the histone acetyltransferase (HAT) CREBBP are common driver events in multiple types of human cancer, such as small cell lung cancer (SCLC) or Sonic Hedgehog medulloblastoma (SHH MB). Therefore, therapeutic options targeting such alterations are highly desired. We used human cell lines from SCLC as well as primary mouse tumor cells and genetically engineered mouse models for SHH MB to test treatment options with histone deacetylase inhibitors (HDACi) in CREBBP wild-type and mutated tumors. In contrast to CREBBP wild-type SCLC cells, CREBBP-mutated SCLC cells showed significantly lower IC50 values after treatment with HDACi. In addition, both in vitro and in vivo, HDACi had significant effects on cell proliferation of SHH-driven tumor MB cells harboring a CREBBP-mutation as compared to CREBBP wild-type controls. These data suggest that HDACi may serve as an additional therapeutic option for patients suffering from tumors driven by CREBBP mutations.


  • TCF4 (E2-2) harbors tumor suppressive functions in SHH medulloblastoma

    by Malte Hellwig, Marlen C. Lauffer, Michael Bockmayr, Michael Spohn, Daniel J. Merk, Luke Harrison, Julia Ahlfeld, Annabel Kitowski, Julia E. Neumann, Jasmin Ohli, et al.

    The TCF4 gene encodes for the basic helix–loop–helix transcription factor 4 (TCF4), which plays an important role in the development of the central nervous system (CNS). Haploinsufficiency of TCF4 was found to cause Pitt-Hopkins syndrome (PTHS), a severe neurodevelopmental disorder. Recently, the screening of a large cohort of medulloblastoma (MB), a highly aggressive embryonal brain tumor, revealed almost 20% of adult patients with MB of the Sonic hedgehog (SHH) subtype carrying somatic TCF4 mutations. Interestingly, many of these mutations have previously been detected as germline mutations in patients with PTHS. We show here that overexpression of wild-type TCF4 in vitro significantly suppresses cell proliferation in MB cells, whereas mutant TCF4 proteins do not to the same extent. Furthermore, RNA sequencing revealed significant upregulation of multiple well-known tumor suppressors upon expression of wild-type TCF4. In vivo, a prenatal knockout of Tcf4 in mice caused a significant increase in apoptosis accompanied by a decreased proliferation and failed migration of cerebellar granule neuron precursor cells (CGNP), which are thought to be the cells of origin for SHH MB. In contrast, postnatal in vitro and in vivo knockouts of Tcf4 with and without an additional constitutive activation of the SHH pathway led to significantly increased proliferation of CGNP or MB cells. Finally, publicly available data from human MB show that relatively low expression levels of TCF4 significantly correlate with a worse clinical outcome. These results not only point to time-specific roles of Tcf4 during cerebellar development but also suggest a functional linkage between TCF4 mutations and the formation of SHH MB, proposing that TCF4 acts as a tumor suppressor during postnatal stages of cerebellar development.


  • GRP78 knockdown does not affect cytotoxicity of cisplatin in ovarian cancer cells

    by Maximilian Kullmann, Sandra Kotz, Malte Hellwig, Ganna V. Kalayda, Sabine Metzger, Ulrich Jaehde


  • Assessing the contribution of the two protein disulfide isomerases PDIA1 and PDIA3 to cisplatin resistance

    by Maximilian Kullmann, Ganna V. Kalayda, Malte Hellwig, Sandra Kotz, Ralf A. Hilger, Sabine Metzger, Ulrich Jaehde